Acinta Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.46%
(FY 2023)
- Profit -396.83%
(FY 2023)
- Ebitda -395.66%
(FY 2023)
- Net Worth -8.46%
(FY 2023)
- Total Assets -11.85%
(FY 2023)
About Acinta Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Praveen Sharma, Meenakshi Sharma, and Yash Sharma serve as directors at the Company.
- CIN/LLPIN
U24233MH2010PTC201377
- Company No.
201377
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Acinta Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Sharma  | Director | 29-Mar-2010 | Current |
| Meenakshi Sharma | Director | 25-Jun-2012 | Current |
| Yash Sharma | Whole-Time Director | 23-Jul-2019 | Current |
Financial Performance and Corporate Structure Insights of Acinta Pharmaceuticals.
Acinta Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.46% increase. The company also saw a substantial fall in profitability, with a 396.83% decrease in profit. The company's net worth dipped by a decrease of 8.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acinta Pharmaceuticals?
In 2023, Acinta Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Surat Hira BourseActive 35 years 2 monthsPraveen Sharma, Meenakshi Sharma and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Acinta Pharmaceuticals?
Acinta Pharmaceuticals has a workforce of 167 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acinta Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acinta Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
